ATP5MC2

Across TCGA pan-cancer cohorts, ATP5MC2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ATP5MC2 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ATP5MC2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATP5MC2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and UCEC show a favorable association.

PDAC, HNSC, and CCRCC are the cancer types where ATP5MC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.283	0.649	.001	28	view →
HNSC	OS	Quartile	III,IV	0.548	1.000	.004	18	view →
CCRCC	DFS	Tertile	All	0.478	1.000	.016	9	view →
LUAD	DFS	Quartile	III,IV	0.960	0.444	.001	6	view →
UCEC	OS	Median	All	1.000	0.899	.028	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ATP5MC2–PDAC (DFS)

Open the PDAC breakdown →